Building a Clear Picture of Your FSGS Diagnosis
At a Glance
FSGS is a pattern of scarring in some kidney filters, not a single disease. Determining whether it is primary, secondary, genetic, or of undetermined cause helps clinicians choose appropriate treatment and avoid unnecessary immune-suppressing medicines.
Receiving a diagnosis of Focal Segmental Glomerulosclerosis (FSGS) can feel overwhelming and confusing. It is a complex term for a complex condition, but understanding what it actually means is the first step in managing your health. Rather than thinking of FSGS as a single disease with one cause, it is helpful to understand it as a pattern of injury [1]. This means that while different people may have the same “FSGS” label on their biopsy report, the reasons they have it—and the way it should be treated—can be very different [2].
What is FSGS?
To understand FSGS, it helps to break down the medical name into plain language:
- Focal: This means that only some of the filters in your kidneys are affected, while others may still look healthy [1].
- Segmental: This means that even in the affected filters, only a portion or “segment” of the filter is damaged [1].
- Glomerulosclerosis: This is the medical term for scarring (sclerosis) of the tiny filtering units of the kidney, called glomeruli [3].
In short, FSGS means that some of your kidney’s filters have developed scar tissue in specific areas. This scarring interferes with the kidney’s ability to filter waste and keep important proteins in your blood. When these filters are damaged, protein “leaks” into your urine, a condition called proteinuria [1].
A Pattern, Not One Disease
One of the most important things to know is that FSGS is not a single disease. Doctors view it as a specific way the kidney reacts to different types of stress or injury [2]. Think of it like a scar on your skin: the scar itself is the “pattern,” but it could have been caused by a burn, a cut, or a scrape. A biopsy alone cannot determine the cause.
To give you the best care, your medical team must determine why that pattern of scarring is happening. The KDIGO 2021 guidelines, which are the international standards for kidney care, categorize FSGS into four main groups based on the cause (etiology) [2][1].
1. Primary FSGS
This is a clinical-pathologic diagnosis, diagnosed based on nephrotic syndrome, diffuse effacement, and the exclusion of secondary and genetic causes. It is proposed to be caused by an unidentified circulating factor in the blood [4].
- Key Signs: It is usually associated with nephrotic syndrome, a cluster of symptoms including high levels of protein in the urine, low protein in the blood, and significant swelling (edema) [5].
- Biopsy Finding: Under a powerful electron microscope, doctors typically see that the “feet” of the podocytes have lost their shape, a finding called diffuse foot-process effacement. This finding is supportive but not unique to primary FSGS [5].
2. Secondary FSGS
In this version, the scarring is a “secondary” result of another condition or stressor. It is often a slower process than primary FSGS [1].
- Causes: It can be caused by the kidney being overworked (maladaptive FSGS), which may happen due to obesity, high blood pressure, or having only one kidney [4][1]. It can also be triggered by certain viruses (like HIV) or specific medications [1].
- Treatment Focus: Unlike primary FSGS, the focus here is usually on treating the underlying cause and protecting the kidneys with blood pressure management rather than strong immune-suppressing drugs [6].
3. Genetic FSGS
Some people have FSGS because of changes (mutations) in their DNA that affect how the kidney filters are built or how they function [4].
- When to Suspect: Doctors may look for genetic causes if you have a family history of kidney disease, if the disease appears at a very young age, or if it does not respond to standard treatments [7].
- Impact: Knowing if FSGS is genetic is vital for families and for planning for a future kidney transplant, as kidney-intrinsic genetic FSGS is much less likely to return in a new kidney compared to primary FSGS [8].
4. FSGS of Undetermined Cause
Sometimes, a biopsy shows the FSGS pattern, but the clinical signs don’t clearly point to primary, secondary, or genetic causes. It is used when the FSGS lesion is present without nephrotic syndrome and without an identified secondary or genetic cause [2]. It is appropriate to receive supportive care and reassessment. The appearance of nephrotic syndrome or new clinical or genetic information may change the classification later [7].
Why Classification Matters
It is natural to feel anxious when you hear these different categories, but this classification is actually a tool to protect you. In the past, many patients were given strong, high-dose steroids because doctors assumed all FSGS was the same [9].
We now know that those treatments—which can have significant side effects—are primarily directed at patients with Primary FSGS who have nephrotic syndrome [6]. They are generally avoided for people with true secondary or kidney-intrinsic genetic forms [10]. By correctly identifying your “type” of FSGS, your doctor can tailor a plan that targets the actual cause of your kidney scarring while avoiding unnecessary medications [2].
Understanding Your Biopsy Variants
Your biopsy report may also use words like collapsing, tip, perihilar, or cellular [2]. These describe exactly where and how the scarring looks under the microscope. While these “variants” provide clues about how the disease might progress, they are separate from the causes listed above. Your doctor will look at both the cause and the variant to build a complete picture of your diagnosis [2].
Common questions in this guide
What does FSGS mean on a kidney biopsy?
What are the main types of FSGS?
Does everyone with FSGS need steroids or immune-suppressing treatment?
What does diffuse foot-process effacement mean?
What do collapsing, tip, perihilar, and cellular FSGS variants mean?
When might genetic testing be useful for someone with FSGS?
What does FSGS of undetermined cause mean?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Focal segmental glomerulosclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Which of the four etiologic categories of FSGS do you believe I fall into, and why?
- 2.Does my biopsy show 'diffuse podocyte foot-process effacement'? How does that finding affect my diagnosis?
- 3.What specific morphologic variant—such as 'tip lesion' or 'collapsing'—was seen on my biopsy?
- 4.Given my family history and age, would genetic testing be helpful for my treatment plan?
- 5.If my diagnosis is 'undetermined,' what additional tests or monitoring will we use to narrow it down?
- 6.Does my current clinical picture meet the full criteria for nephrotic syndrome?
References
References (10)
- 1
Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective.
Shabaka A, Tato Ribera A, Fernández-Juárez G
Nephron 2020; (144(9)):413-427 doi:10.1159/000508099.
PMID: 32721952 - 2
Indications for genetic testing in adults with focal segmental glomerulosclerosis.
Pilco-Terán M, Shabaka A, Furlano M, et al.
Nefrologia 2025; (45(2)):135-149 doi:10.1016/j.nefroe.2025.02.001.
PMID: 39952830 - 3
Pathogenesis of Focal Segmental Glomerulosclerosis.
Lim BJ, Yang JW, Do WS, Fogo AB
Journal of pathology and translational medicine 2016; (50(6)):405-410 doi:10.4132/jptm.2016.09.21.
PMID: 27744657 - 4
Focal Segmental Glomerulosclerosis.
Rosenberg AZ, Kopp JB
Clinical journal of the American Society of Nephrology : CJASN 2017; (12(3)):502-517 doi:10.2215/CJN.05960616.
PMID: 28242845 - 5
What are we missing in the clinical trials of focal segmental glomerulosclerosis?
Zand L, Glassock RJ, De Vriese AS, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2017; (32(suppl_1)):i14-i21 doi:10.1093/ndt/gfw324.
PMID: 28391338 - 6
Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.
Mirioglu S, Daniel-Fischer L, Berke I, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024; (39(4)):569-580 doi:10.1093/ndt/gfae025.
PMID: 38341276 - 7
Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection.
Miao J, Pinto E Vairo F, Hogan MC, et al.
Mayo Clinic proceedings 2021; (96(9)):2342-2353 doi:10.1016/j.mayocp.2021.01.037.
PMID: 34120753 - 8
Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates.
Königshausen E, Sellin L
BioMed research international 2016; (2016()):3765608 doi:10.1155/2016/3765608.
PMID: 27200372 - 9
Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association.
Podestà MA, Ponticelli C
Frontiers in medicine 2020; (7()):604961 doi:10.3389/fmed.2020.604961.
PMID: 33330569 - 10
Podocytopathies.
Kopp JB, Anders HJ, Susztak K, et al.
Nature reviews. Disease primers 2020; (6(1)):68 doi:10.1038/s41572-020-0196-7.
PMID: 32792490
This page explains how FSGS causes and biopsy patterns are classified for informational purposes only and does not constitute medical advice. Your nephrologist or healthcare professional should interpret your biopsy and recommend care for your situation.